|
所在平台: Udemy |
课程主页: https://www.udemy.com/course/cancer-biology-signaling-pathways-and-targeted-therapy-oncology/
课程评论：没有评论
课程名称：癌症信号通路与靶向治疗 课程概述：本课程旨在提供细胞信号传导的基础知识，以及多细胞生物中细胞分裂的控制机制。课程将深入讨论每条信号通路与其相应发展的靶向治疗，强调通过临床试验的真实案例来帮助参与者深入理解靶向治疗的益处以及医学领域面临的挑战。课程结束后，参与者将明白并非所有癌症都有“银弹”解决方案，此外，制药行业如何从患者的组织分型转向基因组分型，这种转变使得他们获得了更好的结果，每年约有40%的FDA批准药物来自这一策略。 课程还将帮助参与者了解某些通路抑制所导致的多种副作用，以及同一通路在不同细胞类型中可能导致的不同结果。课程重点讨论的信号通路包括：MAPK通路、PI3K通路、血管生成-HIF、凋亡-BCL2（即将更新）以及简要介绍PDL1信号。除此之外，课程还将探讨多个已知的致癌突变及其靶向治疗方法。通过本课程，参与者将对癌症信号传导及其靶向治疗有全面而深入的了解。
The course provides the basics of cell signaling and how the cell division is controlled in the multicellular organisms. The course discusses each signaling pathway and the targeted therapies developed for it. Importantly, the course focuses on delivering the real-life examples from clinical trials so that the participant can have a robust idea on the benefits that the targeted therapies provide while being aware of the challenges that face the medical field. The participant at the end of the course has to know that there is no silver bullet for all cancers, not only that but also how the pharmaceutical industry shifted their focus from the histological segmentation of patients to the genomic one, which then rewarded them with better results and more drug approvals that tend to reach up to 40% from total fda approved drugs each year. Last but not least, the participant in that course will get familiar with several side effects of the inhibition of certain pathways, and how the same pathway can lead to different outcomes in different cell types.The course will discuss only the MAPK, PI3K, Angiogenesis-HIF , Apoptosis-BCL2 (soon), and briefly the PDL1 signaling. In addition, the course will discuss several well known oncogenic mutations in the receptors and their targeted therapies.
